Progress to improve, for example, the pharmacokinetic properties (e.g., bioavailability and delivery) of these FGF21-mimicking compounds are now required to improve the efficacy of these therapies against human obesity, IR and T2D. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.